Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MasterAlgaeon Oct 28, 2020 1:34pm
209 Views
Post# 31796386

RE:RE:Sell-off again....

RE:RE:Sell-off again....
Yes, hindsight is always behind me Themagicbox!

Mugs also suggested that shareholders have have money in the bank with the lead and the pipeline.
My concerns are related of course to the lack of news and an uneasy feeling that something is wrong with the lead drug. I suspect it relates to the elevated liver enzimes. It is no benefit to patients or to healthcare providers and insurance companies if the drug requires patients to get liver enzime testing every month while they are taking the drug. That is expensive and physically damaging.

If H2S is damaging with the lead drug it will be damaging with the entire pipeline. That is why I think we've seen the share price plunge since the results came out in June.

The insider buying since is a meaningless token amount especially contrased with the millions cashed in by insiders ("we didn't know honest - look, we bought more shares.")

The recent posts on facebook and twitter smack of 'remedial promotion' which is concerning.

In essense Antibe has only 2 products, dental, and hydrogen sulphide. Hindsight.
Bullboard Posts